SYSTEMATIC REVIEW



Temporomandibular disorders in migraine and tension-type headache patients: a systematic review with meta-analysis

Paolo Bizzarri^{1,2,3,*}, Daniele Manfredini⁴, Michail Koutris⁵, Marco Bartolini⁶, Luca Buzzatti^{1,7}, Cecilia Bagnoli^{2,3}, Aldo Scafoglieri¹

¹Experimental Anatomy Research Group (EXAN), Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium

²Department of Human Neuroscience, University of Rome La Sapienza, 00185 Rome, Italy

³Department of Clinical Science and Translational Medicine, University of Rome "Tor Vergata", 00133 Roma, Italy ⁴Department of Biomedical Technologies, School of Dentistry, University of Siena, 53100 Siena, Italy

⁵Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, Netherlands

⁶Clinic of Neurology, Polytechnic University of Marche, 60126 Ancona, Italy

⁷ School of Allied Health, Anglia Ruskin University, CB1 1PT Cambridge, UK

*Correspondence Paolo.bizzarri@vub.be

(Paolo Bizzarri)

Abstract

The simultaneous occurrence of primary headaches and temporomandibular disorders can pose a challenge in determining the best clinical management of patients. Therefore, we aimed to summarize evidence regarding the risk and prevalence of temporomandibular disorders (TMDs) in migraine and tension-type headaches (TTH) patients. Cross-sectional studies published in English comparing the presence of TMDs in adults with TTH or migraine to subjects without headaches were included, International Classification of Orofacial Pain, Diagnostic Criteria for Temporomandibular Disorders or Research Diagnostic Criteria for Temporomandibular Disorders, and large epidemiological studies (sensitive diagnostic criteria (SDC)). The methodological quality was assessed by Modified Newcastle-Ottawa Quality Assessment Scale. Odds ratio (OR) and random effects were calculated. 1405 articles were identified in PubMed, Embase and Central databases, and 13 cross-sectional studies were finally included. Overall Risk of TMDs was statistically significantly higher than control groups in both Migraine (SDC: 11 studies; OR: 3.79 (2.43, 5.90); $I^2 = 99\%$), with higher values in chronic migraine (OR: 24.27; (95% Confidence interval (CI): 5.84, 100.82); $I^2 = 0\%$) and TTH populations (SDC: 8 studies; OR: 4.45 (2.63, 7.53); $I^2 = 86\%$). Headache subjects presented a higher risk of muscular TMDs (5 studies; OR: 2.01 (1.62, 2.50); I² = 0%), Combined TMDs (5 studies; OR: 2.74 (1.40, 5.36); I^2 = 63%), or Painful TMDs (8 studies; OR: 5.31 (2.96, 9.54); $I^2 = 96\%$). Headache patients didn't show the risk of arthrogenous TMDs (4 studies; OR: 0.96 (0.54, 1.71); $I^2 = 33\%$) or nonpainful TMDs (2 studies; OR: 1.10 (0.28, 4.26); $I^2 = 84\%$). The high heterogeneity in the results was reduced following subgroup analysis. Migraine and TTH appear to increase the risk of painful, myogenous or combined arthrogenous and myogenous TMDs.

Keywords

Primary headaches; Orofacial pain; Association; Temporomandibular joint; Masticatory muscles; Epidemiology

1. Introduction

Headaches are described as the most disabling neurological condition worldwide. Tension-type headache (TTH) is the most prevalent form of headache (22%) and migraine is the most disabling one particularly among females aged 15–49 years [1]. TTH and migraine represent the vast majority of primary headaches, as defined in the International Classification of Headache Disorders (ICHD-3) [2]. Genetic, systemic, hormonal, environmental, psychological and physical factors appear to play a role in the clinical presentations and burden of these disorders. These factors influence peripheral and central mechanisms involved in head and face pain processing, in particular related to the trigeminocervical complex [3–5],

facilitating segmental and general comorbidities. People with headaches often report sleep disorders, anxiety, depression and painful comorbidities, both in surrounding areas (face and neck pain) and widespread regions (back pain and fibromyalgia) [6–8]. Moreover, the risk of suffering from headaches has been described to increase from twofold to threefold in adult women compared to men [9], supporting the role of hormonal factors (mainly related to estrogens and progesterone) [10]. Female sex, sleep disorders, psychological and painful comorbidities are also risk factors for temporomandibular disorders [11–14].

Temporomandibular disorders (TMD) are defined as a group of musculoskeletal and neuromuscular conditions that involve the temporomandibular joints (TMJs), the masticatory muscles and all associated tissues. As described in the Axis I of the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) [15], the main TMD categories are temporomandibular joint and masticatory muscle disorders, the prevalence of which ranges between 5% and 12% [16]. The distinction between these categories is based mainly on painful symptoms, biomechanical signs and structural alterations. Nociceptive signals from such peripheral structures, mainly innervated by the mandibular branch of the trigeminal nerve, can sensitize the trigeminocervical complex and modulate head pain [5]. The International Classification for Headache Disorders includes the condition. Headache attributed to temporomandibular disorder (TMD), a secondary headache caused by a disorder involving structures in the temporomandibular region (ICHD).

Even though isolated facial pain has been described as rare in primary headache populations [17], TMDs appear to be more prevalent in headache populations compared to non-headache subjects. Likewise, headache has been described as one of the most common comorbidities in subjects with TMD [18]. This overlap, often overlooked in clinical practice, can be challenging and critical in determining the best management of patients as well as in achieving a proper diagnosis early in the assessment phase. The presence of painful TMDs in subjects with primary headaches has been associated with higher headache frequency in adolescents [19]. However, the available literature lacks strong evidence that clarifies the relationship between primary headaches and TMDs. Most articles do not apply reference standards, such as DC/TMD [15], ICHD-3 [2] and ICOP [20], for categorizing patients. Moreover, reported data often refer exclusively to signs and symptoms, and lack non-headache control groups, inadvertently reducing the external validity of these findings.

Yakkaphan *et al.* [21] recently published a systematic review on the reciprocal association between TMDs and headaches. This review included studies without reference standard diagnostic criteria, and lacks the analysis of subgroups of primary headaches (*e.g.*, chronic forms). No systematic review has been published on this subject related to reference diagnostic criteria and large epidemiological studies. Therefore, we aimed to compare the risk of specific TMDs diagnoses in migraine and TTH patients and non-headache adult populations.

2. Materials and methods

The guidelines of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group [22] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines [23] were followed for this review. The protocol of this systematic review was registered in the PROSPERO database (CRD42020167535).

2.1 Data sources

We aimed to include cross-sectional studies published in English comparing the presence of specific TMD diagnoses in adults with primary headaches to adults without headaches. Preliminary electronic searches retrieved no studies with Trigeminal autonomic cephalalgias (TACs) or other primary headache disorders except for Migraine and Tension-Type Headaches (TTH). Therefore, this study and the search strategy focused on the latter two. A first electronic search was performed in PubMed, Embase and Central databases, on 19 September 2020. A second search was performed on 09 May 2022. The full search strategy is available in **Supplementary material**.

2.2 Study selection

No time restriction was applied to search strategies. The reference lists of the included studies were searched to retrieve supplemental primary articles of interest, using Rayyan website (https://www.rayyan.ai/) [24].

To be included, studies were required to be cross-sectional studies reporting data on the prevalence of diagnosis of TMD in a group of subjects with a specific diagnosis of migraine, TTH and a control group of non-headache subjects.

Studies and data regarding Chronic Daily Headache or headache symptoms without specific diagnoses were excluded for better adherence to ICHD-3 [2]. However, we didn't restrict headache diagnoses specifically to ICHD criteria with the aim of including population-based studies. If a study reported data regarding both migraine or TTH, and other headaches, only data respecting our inclusion criteria were extracted.

Case reports, studies based on adolescent and paediatric populations, and studies regarding Infrequent Episodic TTH (IETTH) were also excluded to improve the external validity of our findings.

Due to the high variability of TMD classifications, and in order to simplify data analysis, we accepted diagnostic criteria for TMD as described in the single studies, if they respected our inclusion criteria. However, the term "facial pain" was not considered, given its possible overlap with clinical presentation of odontogenic pain, trigeminal neuralgia, migraine and TTH patients [25].

In preparing and summarizing our findings, we aimed to adhere to ICOP terminology and diagnostic disorders [20].

2.3 Study inclusion and data extraction

Two independent reviewers (PB, CB) screened all articles by title, abstract and full texts using Rayyan website [24]. Disagreements were resolved by consensus or by consulting a third investigator (LB). For each study, two reviewers independently extracted data regarding study design, setting, age, gender, diagnostic criteria and modalities, the total number of subjects with specific headaches and control groups, the total number of subjects with and without TMD diagnosis, signs and symptoms. In need of clarifications, especially regarding the inclusion of data in subgroup analyses, corresponding authors of retrieved studies were contacted via email. Two reviewers (PB, CB) assessed study quality using the Modified-Newcastle Ottawa Scale (M-NOS) for cross-sectional studies [26]. The tool assesses three domains: selection (four items), comparability (two items) and exposure (three items). A total of nine points are awarded, with higher sum scores reflecting superior study quality.

2.4 Data synthesis

The results of individual studies comparing the presence of TMD in subjects with and without primary headaches were pooled using the Mantel-Haenszel method with a randomeffects model. Odds Ratio (OR) was chosen as the effect measure and corresponding 95% confidence intervals (CI) were calculated. Forest plots were created for graphical representation of the results. Heterogeneity was assessed by inspection of the CI from the forest plots, Chi-squared tests for heterogeneity and I^2 statistics (<50% representing low heterogeneity, between 50% and 75% representing moderate heterogeneity, and greater than 75% representing high heterogeneity) [27]. Subgroup analysis was performed using different categories of primary headaches (tension-type headaches and migraine) and further stratification by type of TMD (joint, muscular or combined). In order to verify whether subgroup results were genuinely different, tests for subgroup differences were computed (*p*-value, I^2). All analyses were performed in Review Manager 5.3 (RevMan-Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Denmark).

3. Results

The first database search identified 1405 results. After the removal of duplicates, and title and abstract screening, 92 full texts were examined. The second search was performed on 09 May 2022, retrieving 93 additional articles. No additional study was eligible. As described in the PRISMA flow chart (Fig. 1), 13 [28–40] cross-sectional studies met our inclusion criteria and were included in our qualitative synthesis. The main causes of exclusion were related to a non-specific diagnosis of headache, or the lack of subjects without headaches in the control group. Analysis of publication bias is reported in Fig. 2. The exclusion of the outlier [32] did not produce changes in the heterogeneity of results.

The following information was extracted from each publication selected for inclusion: Setting, Design, Inclusion Criteria, Headache (HA) and TMD diagnostic criteria, HA and TMD prevalence, age, gender distribution. Prevalence of temporomandibular disorders in patients with primary headaches and controls was computed for each study.

3.1 Characteristics of the studies

Headache diagnoses were made following ICHD criteria in 8 studies, whereas Research Diagnostic Criteria (RDC/TMD) or Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) were used in 7 studies. ICOP classification was not performed in the included studies. 9 studies applied questionnaires for headache or TMD diagnoses. Thus, the terminology was not consistent throughout the articles. Five articles applied gold standard diagnostic classifications for both primary headaches and TMDs, thus results from these studies will be presented separately. To simplify data analysis, however, we accepted diagnostic criteria as described in single studies, if they respected our inclusion criteria. Full data descriptions are reported in Tables 1,2,3.

3.2 Quality of the studies

The methodological quality scores ranged from 4 to 7 out of a maximum of 9 (Table 3).

3.3 TMD risk in headache populations

The following presentation of TMD prevalence does not discriminate between specific TMD clinical characteristics. Specific subgroup analyses are shown afterwards in this article.

3.3.1 TMD in headache patients—reference classifications

Five studies [28–32], all of which were clinically based, used a reference classification for both primary headaches (ICHD-3 or ICHD-2) and TMDs (RDC/TMD). Overall risk of suffering from TMDs was significantly higher in headache subjects than in non-headaches control groups (Prevalence: 82.9% vs. 42.4% OR 8.11 (95% CI: 2.58, 25.48); $I^2 = 91\%$) (Fig. 3).

TMDs are also more prevalent in migraine patients compared to control groups (4 studies; 82.4% vs. 52.3%; OR 4.78 (95% CI: 2.16, 10.58); $I^2 = 69\%$) (Fig. 4), so as in TTH subjects (4 studies; 82.96% vs. 43.51%; OR 7.41 (95% CI: 1.50, 36.57); $I^2 = 87\%$) (Fig. 5).

3.3.2 TMD in headache patients following sensitive diagnostic criteria

3.3.2.1 Overall TMD risk in Migraine—sensitive diagnostic criteria

Irrespective of diagnostic criteria, 11 studies analysed the prevalence of TMD diagnosis in migraineurs compared to non-headache subjects. Studies were heterogeneous regarding setting, data collection and diagnostic criteria and modalities. Most studies didn't differentiate migraine types. One study [36] distinguished between episodic and chronic migraine, one study [31] between migraine and probable migraine, and one study [30] between migraine and chronic migraine.

The pooled prevalence of TMD was 6.7% in migraineurs, whereas the prevalence of TMD in the non-headache population was 0.4%, with OR 3.79 ((95% CI: 2.43, 5.90); $I^2 = 99\%$).

One clinically based study [36] reported a prevalence of TMD of 77.4% in episodic migraine patients, compared to 53.1% in non-headache subjects, with OR 3.03 (95% CI: 1.02, 9.01). For chronic migraine, two clinically based studies [30, 36] observed a pooled prevalence of TMD in 95.4%, compared to 43.5% in control groups, with OR: 24.27 ((95% CI: 5.84, 100.82); $I^2 = 0\%$) (Fig. 6).

3.3.2.2 Overall TMD risk in tension-type headache—sensitive diagnostic criteria

8 studies analysed the prevalence of TMD diagnosis in TTH patients compared to non-headache subjects. Study characteristics varied regarding setting, data collection, diagnostic criteria and modalities. One study distinguished between Frequent episodic TTH (FETTH) and chronic TTH (CTTH) [34]. Due to the low frequency of CTTH prevalence, related data was not presented by the authors. One study [31] distinguished between TTH and probable TTH.

The pooled prevalence of TMD was 7.9% in TTH patients, whereas the prevalence of TMD in non-headache population




FIGURE 1. PRISMA search-flow diagram.




FIGURE 2. Funnel plot for publication bias of all studies included. OR: Odds Ratio; SE: Standard Error.

			diagn	oses.			
Author and Year	Country	Setting	Sample Size	Diagnostic Criteria for HA	Headaches Included	Diagnostic Criteria for Temporo- mandibular disorders	TMD Included
Franco 2010	Brazil	TMD and Orofacial Pain Clinic	n. HA: 161 n. Control: 37	ICHD-II Based Questionnaire	• Migraine • TTH	RDC/TMD	 Myofascial Pain Arthralgia Combined
Goncalves 2011	Brazil	University— based specialty clinic.	n. HA: 235 n. Control: 65	Questionnaire based on ICHD-II	• Migraine • ETTH	RDC/TMD— Questionnaire and Physical Examination	• jTMD • mTMD Combined TMD
Goncalves 2013	Brazil	University— based headache outpatient clinic (tertiary care)	n. HA: 61 n. Control: 30	ICHD-II— Neurologist	 Migraine Chronic Migraine 	RDC/TMD Axis I— Physiotherapists	• Group I • Group I + II • Group I + III Group I + II + III
Van der Meer 2017	Netherlands	Clinic for TMD and orofacial pain of the academic centre for dentistry, Amsterdam	n. HA: 137 n. Control: 66	ICHD-3— Headache Screening Question- naire. Migraine and TTH	 Migraine Probable Migraine TTH Probable TTH HA attributed to TMD 	RDC/TMD	• Painful TMD • Function related TMD
Wagner 2019	Brazil	Orofacial Pain Clinic	n. HA: 90 n. Control: 72	Neurologist— Questionnaire on ICHD-3 beta	Frequent TTH	RDC/TMD	 Painful TMD Non-Painful TMD

TABLE 1. Overview of included studies that applied reference classifications for primary headache and TMD diagnoses.

HA: Headache; ICHD: International Classification of Headache Disorders; TMD: Temporomandibular Disorders; jTMD: Joint TMD; mTMD: Myogenous TMD; TTH: Tension-Type Headache; ETTH: Episodic TTH; RDC/TMD: Research Diagnostic Criteria for Temporomandibular Disorders.

was 0.3%, with OR 4.45 ((95% CI: 2.63, 7.53); $I^2 = 86\%$).

Two studies published by the same research group [29, 37], one population-based and one clinic-based, considering ETTH diagnoses based on questionnaires, reported pooled prevalence of TMD of 40.7% in headache patients, and 17.8% in nonheadache subjects (OR 3.06 (95% CI: 1.90, 4.94); $I^2 = 21\%$).

One study regarding CTTH, based on a community database of twins [40], reported TMD prevalence of 12.4% in headache patients and 4.4% in non-headache subjects (OR 3.10 (95% CI: 2.14, 4.49)) (Fig. 7).

3.3.3 Risk of specific TMD diagnoses in headaches

3.3.3.1 Arthrogenous TMD in headache patients

4 studies [28, 29, 33, 34] assessed the prevalence of Arthrogenous TMD in migraineurs, which was reported as 3.1%, compared to 1.8% in control groups, without statistical differences between groups. Arthrogenous TMD was present in 8.8% of TTH subjects evaluated in 3 studies [28, 29, 34], while the control group's prevalence was 8.7%. No difference was observed.

			diagi	ioses.			
Author and Year	Country	Setting	Sample Size	Diagnostic Criteria for HA	Headache Included	Diagnostic Criteria for Temporo- mandibular disorders	TMD Included
Ashraf 2019	Finland	National survey	n. HA: 498 n. Control: 5378	Previous Diagnosis	• Migraine	Clinical Examination based on RDC/TMD	 jTMD mTMD Combined TMD
Benoliel 2010	Israel	Medical and dental students	n. HA: 299 n. Control: 60	Questionnaire based on HIS (ICHD-2)	 Migraine FETTH IETTH CTTH 	Questionnaire based on AAOP and RCD/TMD Criteria	 jTMD mTMD Combined TMD
Fenton 2016	USA	Musculoskeletal Disorder Cohort (MSD) cohort for Veterans	n. HA: 167,597 n. Controls: 3,960,391	Previous Diagnosis	• Migraine • Tension Headache	TMD was defined as ICD codes 524.29, 524.6, 524.60, 524.61, 524.62, 524.63, 524.64 and 524.69	• TMD
Florencio 2017	Brazil	Tertiary university based hospital	n. HA: 52 n. Control: 32	ICHD-III— Examination (Neurologist)	 Episodic Migraine Chronic Migraine 	Fonseca Anamnestic Index	Mild TMDSevere TMD
Goncalves 2010	Brazil	Urban Population	n. HA: 472 n. Control: 676	Questionnaire based on ICHD-II	• Migraine • ETTH	Questionnaire based on AAOP	• TMD
Plesh 2012	USA	National Survey—US. National Health Interview Survey (NHIS)	n. HA: 29,712 n. Control: 160,255	Questionnaire	• Mi- graine/Severe Headache	Questionnaire	TMJMDs Pain— Temporomandi- bular joint and muscle disorders pain
Song 2018	South Korea	Dataset of national survey	n. HA: 3940 n. Control: 17,575	Previous History in Survey	• Migraine	Signs and Symptoms	TMD
Schur 2007	USA	University of Washington Twin Registry (UWTR)— community- based registry	n. HA: 315 n. Control: 3622	Questionnaire on Previous Diagnosis	• Chronic Tension Headache	Questionnaire on Previous Diagnosis	• TMJ Syndrome

TABLE 2. Overview of included studies that applied sensitive diagnostic criteria for primary headache and TMD diagnoses.

HA: Headache; ICHD: International Classification of Headache Disorders; TMJ: Temporomandibular Joint; TMD: Temporomandibular Disorders; jTMD: Joint TMD; mTMD: Myogenous TMD; TTH: Tension-Type Headache; FETTH: Frequent Episodic TTH; IETTH: Infrequent Episodic TTH; CTTH: Chronic Tension-Type Headache; RDC/TMD: Research Diagnostic Criteria for Temporomandibular Disorders; AAOP: American Academy of Orofacial Pain.

				Cross-sectiona	l studies			
Study		Se	election		Compa	arability	O	utcome
	Represen- tativeness of the sample	Sample size	Nonres- pondents	Ascertainment of the exposure	The study controls for the most important confounding factor	The study controls for any additional confounding factor	Assess- ment of outcome	Statistical test
Ashraf, 2019	*			*	*	*	**	*
Benoliel, 2010				**			*	*
Fenton, 2018	*			**	*		**	*
Florencio, 2017	*	*		**			*	*
Goncalves, 2009	, *	*		**			*	*
Goncalves 2013				**			**	*
Jussila, 2018				*			**	*
Van Der Meer, 2017	*	*	*		*	*	*	*
Plesh, 2012	*			*	*	*	*	*
Schur, 2007	*			*	*	*	*	*
Song, 2018	*			*	*	*	*	*
Steele, 1991	*			*			**	*
Wagner, 2019				**			*	*

TABLE 3. Methodological quality of the studies.

~

. 1 . 1

Stars are assigned for a study's design characteristics. Studies that garner more stars are deemed to be of higher quality.

	Headaches C	Groups	Control G	roups		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl
Franco, 2010	130	161	22	59	20.8%	7.05 [3.66, 13.61]		_ _ _
Goncalves, 2011	124	147	36	65	20.7%	4.34 [2.24, 8.41]		
Goncalves, 2013	54	61	10	30	18.5%	15.43 [5.17, 46.06]		
Van der Meer, 2017	151	192	47	66	20.8%	1.49 [0.79, 2.81]		+
Wagner, 2019	81	90	9	72	19.1%	63.00 [23.62, 168.00]		
Total (95% Cl)		651		292	100.0%	8.11 [2.58, 25.48]		
Total events	540		124					
Heterogeneity: Tau ² =	1.53; Chi ² = 44	.56, df = 4	4 (p < 0.000	01); l² =	91%			
Test for overall effect:	Z = 3.58 (<i>p</i> = 0	.0003)	••				0.005	0.1 1 10 200 Favours Control Group Favours Headache Group

FIGURE 3. Overall risk of TMD in headache patients (Reference Classifications). CI: confidence intervals.


	Migraine (Group	Control (Group		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Franco, 2010	84	105	22	59	29.1%	6.73 [3.30, 13.71]	_
Goncalves, 2011	87	104	36	65	29.1%	4.12 [2.02, 8.42]	_
Goncalves, 2013	21	23	10	30	14.5%	21.00 [4.09, 107.94]	
Van der Meer, 2017	57	70	47	66	27.3%	1.77 [0.79, 3.96]	+
Total (95% CI)		302		220	100.0%	4.78 [2.16, 10.58]	
Total events	249		115				
Heterogeneity: Tau ² =	0.43; Chi ² =	9.81, df	= 3 (<i>p</i> = 0.	02); I ² =	69%		
Test for overall effect:							0.01 0.1 1 10 100 Favours Control Group Favours Migraine Group

FIGURE 4. Risk of TMD in migraine (Reference Classifications). CI: confidence intervals.

	TTH Gr	oup	Control C	Group		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
Franco, 2010	46	56	22	59	25.1%	7.74 [3.26, 18.35]	
Goncalves, 2011	37	43	36	65	24.5%	4.97 [1.84, 13.39]	
Van der Meer, 2017	94	122	47	66	25.8%	1.36 [0.69, 2.68]	
Wagner, 2019	81	90	9	72	24.6%	63.00 [23.62, 168.00]	
Total (95% CI)		311		262	100.0%	7.41 [1.50, 36.57]	
Total events	258		114				
Heterogeneity: Tau ² = Test for overall effect:				< 0.000	01); l² = 9	3%	Image: https://www.amage.org/additionality.com/additionaditionadity.com/additacity.com/additionality.com/additionality.co

FIGURE 5. Risk of TMD in TTH (Reference Classifications). CI: confidence intervals.

	Heada	ches	Cor	ntrol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% Cl
5.1.1 Episodic Migrai	ine						
Florencio, 2017 Subtotal (95% CI)	24	31 31	17	32 32	6.3% 6.3%	3.03 [1.02, 9.01] 3.03 [1.02, 9.01]	-
Total events	24		17				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.99 (<i>p</i> = 0.05)				
5.1.2 Chronic Migrain	ne						
Florencio, 2017	21	21	17	32	1.8%	38.09 [2.13, 682.55]	
Goncalves, 2013	21	23	10	30	4.2%	21.00 [4.09, 107.94]	
Subtotal (95% CI)		44		62	6.0%	24.27 [5.84, 100.82]	
Total events	42		27				
Heterogeneity: Tau ² =	0.00; Chi ²	² = 0.13,	df = 1 (<i>p</i>	= 0.72); l ²	= 0%		
Test for overall effect:	Z = 4.39 (<i>p</i> < 0.00	01)				
5.1.3 Unspecified Mig	graine						
Ashraf, 2019	112	498	768	5378	10.3%	1.74 [1.39, 2.18]	+
Beloniel, 2010	9	69	5	60	6.0%	1.65 [0.52, 5.23]	
Fenton, 2018	769	64075	10916	3960394	10.5%	4.39 [4.08, 4.73]	
Franco, 2010	84	105	22	59	8.2%	6.73 [3.30, 13.71]	
Goncalves, 2009	112	239	96	676	9.9%	5.33 [3.82, 7.44]	-
Goncalves, 2011	87	104	36	65	8.2%	4.12 [2.02, 8.42]	
Goncalves, 2013	33	38	10	30	5.8%	13.20 [3.94, 44.21]	
Plesh, 2012	4635	29712	4166	160255	10.5%	6.93 [6.63, 7.24]	•
Song, 2018	611	3940	1399	13319	10.5%	1.56 [1.41, 1.73]	-
Van der Meer, 2017	57	70	47	66	7.7%	1.77 [0.79, 3.96]	
Subtotal (95% CI)		98850		4140302	87.7%	3.61 [2.28, 5.73]	\bullet
Total events	6509		17465				
Heterogeneity: Tau ² =	,			(<i>p</i> < 0.000	01); l² = 9	9%	
Test for overall effect:	∠ = 5.46 (<i>p</i> < 0.00	001)				
Total (95% CI)		98925		4140396	100.0%	4.01 [2.61, 6.18]	•
Total events	6575		17509				
Heterogeneity: Tau ² =	,		•	2 (<i>p</i> < 0.00	001); l² = 9	99%	0.001 0.1 1 10 10
Test for overall effect:	Z = 6.31 (<i>p</i> < 0.00	001)				TMD without Headachs TMD with Headachs
Test for subgroup diffe	erences: C	hi² = 6.5	8, df = 2	(p = 0.04),	l² = 69.6%	6	






FIGURE 7. Risk of TMD in TTH—Sensitive diagnostic criteria. CI: confidence intervals.

Headache patients did not show to be at higher risk of Arthrogenous TMD (OR 0.96 (95% CI: 0.54, 1.71); $I^2 = 33\%$) compared to non-headache samples.

3.3.3.2 Myogenous TMD in headache patients

5 studies [28–30, 33, 34] compared the prevalence of myogenous TMD in migraine, which was observed in 19.1% of the study group, compared to 10.7% in control groups (OR 1.96 (95% CI: 1.56, 2.45)). Myogenous TMD was also more prevalent in 3 [28, 29, 34] studies including TTH subjects (12.2%) compared to control groups (4.3%) (OR 3.03 (95% CI: 1.29, 7.15)).

Pooled risk of myogenous TMD in primary headache subjects was calculated as OR 1.97 ((95% CI: 1.57, 2.46) with I^2 = 0%. (Pooled prevalence 18.03% vs. 10.71%).

3.3.3.3 Combined joint and myogenous TMD in headache patients

5 studies [28–30, 33, 34] assessed the prevalence of combined TMD in migraineurs, which was calculated as 19.5%, compared to 2.5% in control groups (OR 2.74 (1.40, 5.36); $I^2 = 63\%$). Combined TMD was also present in 40.1% of TTH subjects evaluated in 3 studies [28, 29, 34], while control groups prevalence was 21.2% (OR 2.81 (95% CI: 1.77, 4.46); $I^2 = 47\%$).

3.3.3.4 Painful TMD in headache patients

Pooled results from 8 studies [28, 30–34, 37, 38] resulted in 16.8% prevalence of painful TMD in headache subjects, compared to 3.0% in non-headache populations (OR 5.31 (95% CI: 2.96, 9.54); $I^2 = 96\%$).

Prevalence of Painful TMD was 16.3% in migraineur subjects, compared to 3.0% in non-headache populations (7 studies; OR 4.66 (95% CI: 2.49, 8.70); $I^2 = 96\%$).

5 studies showed a prevalence of 43.0% of painful TMD in TTH patients, compared to 15.1% in control groups (OR 4.94 (95% CI: 2.02, 12.06); $I^2 = 86\%$).

3.3.3.5 Non-Painful TMD in headache patients

Data from 2 studies [31, 32] showed a pooled 31.3% prevalence of non-painful TMD in headache patients, compared to 36.3% in non-headache subjects (OR 1.10 (95% CI: 0.28, 4.26); $I^2 = 78\%$) (Fig. 8).

4. Discussion

Overall prevalence of TMD is higher in subjects with migraine and/or TTH than in non-headache individuals. Specifically, based on a subgroup analysis of studies based on reference diagnostic procedures, painful TMDs were more prevalent in TTH (OR 13.36 (95% CI: 3.01, 59.29)) and migraine (OR




FIGURE 8. Risk of painful and non-painful TMD in Headache patients—Sensitive diagnostic criteria. CI: confidence intervals.

6.81 (95% CI: 3.50, 13.24)) subjects, whereas arthrogenous disorders were not.

These findings support a clinical relationship between TMDs and primary headaches. Studies have also shown a higher prevalence of subclinical signs and symptoms, such as masticatory muscle and TMJ tenderness, in primary headache patients [41–43]. Moreover, the presence and higher intensity of temporomandibular pain in headache patients are associated with higher headache intensity, frequency, disability and medication intake [28, 33, 36]. In our review we observed the highest prevalence in chronic migraine patients (OR 24.27). Therefore, these findings may have a high clinical impact on the assessment and management of patients with headaches.

Migraine, TTH and TMDs, as different entities, share several mechanisms in pain processing, and central sensitization appears to play a major role in this process. The trigeminocervical complex mediates both head and face pain, therefore regional sensitization due to peripheral or central factors can facilitate, aggravate, or perpetuate craniofacial pain [44]. Allodynia or reduced pressure pain threshold (PPT) have been observed on trigeminal and C1–C3 segments in both headaches and TMD populations, with higher values in patients with both these conditions [45], supporting TMD as perpetuating or aggravating factors of headaches.

History of micro-trauma (bruxism) or macro-trauma (facial trauma) in craniofacial anatomical regions are also reported in both these populations, suggesting a role of peripheral inputs in painful symptoms [46]. From a clinical point of view, a higher prevalence of neck pain and disability or otologic symptoms [39, 47], suggests a segmental involvement and

clinical overlap in describing these clinical presentations.

However, pain processing involving supraspinal mechanisms also appears to play a role in these relationships. High prevalence of widespread and systemic painful comorbidity and structural and functional changes on MRI have been observed in both these populations [38, 48–51].

Migraine and TTH are primary headaches in nature, therefore capable of amplifying peripheral nociception.

Female subjects have shown a higher prevalence of TTH, migraine and/or TMDs, compared to males [16, 52]. Such prevalence has been previously attributed to several factors, including hormonal factors (*e.g.*, estrogens), due to the higher TMD prevalence and dysfunction in reproductive age [53]. However, although the link between hormones and headaches is well established, the literature lacks evidence regarding hormonal roles in TMDs.

Headache populations have been reported to suffer from depressive symptoms, anxiety and emotional distress [54]. Psychological aspects have been observed as key factors in subjects with TMD, to the extent, the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) [55], and later on the DC/TMD comprise the Axis II, a specific assessment of psychological status and pain-related disability [15]. They have been linked to craniofacial pain in a bidirectional relationship. Painful symptoms can be easily considered as responsible for the psychological dimensions of pain experience. On the other hand, psychosocial impairments have been linked to higher perceived distress and disability in cross-sectional studies [56] and represent a risk factor for first-onset TMDs [57] as well as for poor prognosis [58].

Higher psychological distress has also been linked to oral

habits (*e.g.*, onychophagia, chewing-gum use) and awake bruxism [59]. Such behaviours, observed in both headache and TMD patients [32, 60], can be enhanced by higher psychological distress [61–63], with or without painful symptoms. They can also represent a peripheral cause of nociception or a perpetuating factor due to masticatory muscles and TMJ overload [64, 65].

Most of these factors, as well as other aspects related to respiratory or oral health (*e.g.*, obstructive sleep apnea), could play as confounders of the causative association between headaches and TMDs. However, such features were not controlled in most of the included studies, and the methodological quality of the available literature regarding these topics is low, therefore no firm conclusion can be drawn [31, 32, 66–68].

Painful TMD may contribute to primary headache clinical presentation [69]. Even though studies on the efficacy of TMD management (*e.g.*, oral splint therapy) in primary headache patients have shown unsatisfying results [70], TMD treatment could be useful in patients with this specific comorbidity as an approach to clean the clinical picture. Preliminary findings appear promising on this topic [71]. On the other hand, a program of 10 weeks of Propranolol (Beta-blockage) has shown to be effective in improving TMD pain in subjects with both TMD and migraine [72].

Arthrogenous TMD and non-painful TMD did not appear to be associated with primary headaches. As described in the DC/TMD classification system, joint disorders include anatomical and biomechanical changes in the normal anatomy of the temporomandibular joint, mainly regarding disc displacements or degenerative changes. This can be diagnosed through clinical examination, mainly through the identification of joint sounds and functional limitations. The gold standard in the diagnosis of joint TMD is medical imaging (Magnetic resonance imaging for soft tissue, computed tomography for bone changes) [15] (Schiffman 2014), which should be prescribed upon need [73, 74]. This category does not mandatorily imply the presence of painful symptoms reported by the patient or reproduced by the examiner. Such findings support the relatively scarce role of structural alteration of temporomandibular joints in most orofacial pain presentations, both in primary headaches and in pain of temporomandibular origin.

The different clinical impact of painful and structural TMD has been an important focus in implementing high-quality management of patients with orofacial pain, in a path that led to the development of the International Classification of Orofacial Pain [20, 75, 76]. The process that led to the publication of ICOP was much needed due to the high heterogeneity observed in studies on the face and head pain, as we also could see developing this systematic review. From all studies included, only five reported the reference classification for both TMD (RDC/TMD, DC/TMD or ICOP) and headaches (ICHD-2 or ICHD-3) (Section 2 of the results). High heterogeneity in inclusion criteria however showed similar results between data from more sensitive or specific inclusion criteria, underlining the higher prevalence of painful TMD in migraine and TTH patients, but not for arthrogenous TMDs. These findings support our choice to include all studies referring to primary headaches and TMDs, intending to analyse and summarize the whole literature on this topic.

Studies regarding face or head pain without a specific diagnosis were excluded from this review. Headache as a symptom has been described as one of the most prevalent comorbidities in patients with TMD. Moreover, even if isolated face pain is rare in primary headaches [77, 78], face signs and symptoms, such as fatigue, reduced pressure pain threshold, discomfort or perceived difficulties in the mandibular movement are often reported by headache patients.

We excluded IETTH from our review. Due to the high prevalence and limited impact on the quality of life and disability of these conditions our analysis could have been impacted, reducing the external validity of our findings. We also excluded data regarding Chronic Daily Headaches. This diagnostic term is not included in the ICHD-3. Since this term could encompass several headache disorders (*e.g.*, chronic or transformed migraine, chronic tension-type headache (CTTH), new daily persistent headache and hemicrania continua) [79], we considered such studies not suitable for our review.

Preliminary results from this SR were presented as posters at the International Headache Society and European Headache Federation Joint Congress 2021 and the American Headache Society Congress 2021.

5. Limitations

This systematic review presents exclusively cross-sectional studies, which design does not imply causation between these conditions. However, recent studies have shown that suffering from migraine, mixed headache or headache frequency at baseline increased the risk of developing TMD at 5 years follow-up [80], and a diagnosis of TMD has been described as a risk factor for the first diagnosis of migraine in 5 years follow up [81].

Data from studies included could be biased in several ways, due to heterogeneity in setting, diagnostic procedure and data collection heterogeneity. Our choice for a subgroup analysis based on diagnostic procedure, and the presence of painful/non-painful TMD however appeared to decrease the heterogeneity in the results of our meta-analysis.

6. Conclusions

TTH and migraine patients appear to be more prone to temporomandibular disorders compared to non-headache subjects. Possible comorbidities should be considered in the assessment of patients with craniofacial pain.

7. Highlights

• Patients with migraine or Tension-type headaches have a higher risk of painful, myogenous or mixed temporomandibular disorders compared to non-headache subjects.

• Prevalence of arthrogenous TMD or non-painful TMD was similar between headache and non-headache populations.

• These findings should be considered during assessment and management of patients with migraine or tension-type headaches.

The data presented in this study are available on reasonable request from the corresponding author.

AUTHOR CONTRIBUTIONS

PB and AS—conceived the presented idea and the research design. PB and CB—performed the electronic search, acquired the data and performed the analysis of the risk of bias. LB—analyzed and interpreted the data. PB, DM, MK, MB, LB, CB and AS—wrote and reviewed the paper. All authors approved the final version of the manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

ACKNOWLEDGMENT

Not applicable.

FUNDING

This research received no external funding.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

SUPPLEMENTARY MATERIAL

Supplementary material associated with this article can be found, in the online version, at https://files.jofph.com/ files/article/1800767281587732480/attachment/ Supplementary%20material.docx.

REFERENCES

- [1] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020; 396: 1204–1222.
- [2] Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018; 38: 1–211.
- [3] Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system—40 years and counting. The Lancet Neurology. 2019; 18: 795–804.
- [4] Ashina M, Terwindt GM, Al-Karagholi MA-M, de Boer I, Lee MJ, Hay DL, *et al.* Migraine: disease characterisation, biomarkers, and precision medicine. The Lancet. 2021; 397: 1496–1504.
- [5] Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. Current Pain and Headache Reports. 2003; 7: 371–376.
- [6] Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome. Clinical Rheumatology. 2005; 24: 595–601.
- [7] Ashina S, Lipton RB, Bendtsen L, Hajiyeva N, Buse DC, Lyngberg AC, et al. Increased pain sensitivity in migraine and tension-type headache

coexistent with low back pain: a cross-sectional population study. European Journal of Pain. 2018; 22: 904–914.

- [8] Vgontzas A, Pavlović JM. Sleep disorders and migraine: review of literature and potential pathophysiology mechanisms. Headache. 2018; 58: 1030–1039.
- [9] Todd C, Lagman-Bartolome AM, Lay C. Women and migraine: the role of hormones. Current Neurology and Neuroscience Reports. 2018; 18: 42.
- ^[10] Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American migraine prevalence and prevention (AMPP) Study. Headache. 2013; 53: 1278–1299.
- [11] Greene CS, Manfredini D. Transitioning to chronic temporomandibular disorder pain: a combination of patient vulnerabilities and iatrogenesis. Journal of Oral Rehabilitation. 2021; 48: 1077–1088.
- [12] De La Torre Canales G, Câmara-Souza MB, Muñoz Lora VRM, Guarda-Nardini L, Conti PCR, Rodrigues Garcia RM, *et al.* Prevalence of psychosocial impairment in temporomandibular disorder patients: a systematic review. Journal of Oral Rehabilitation. 2018; 45: 881–889.
- ^[13] Slade GD, Ohrbach R, Greenspan JD, Fillingim RB, Bair E, Sanders AE, *et al.* Painful temporomandibular disorder: decade of discovery from OPPERA studies. Journal of Dental Research. 2016; 95: 1084–1092.
- [14] List T, Jensen RH. Temporomandibular disorders: old ideas and new concepts. Cephalalgia. 2017; 37: 692–704.
- ^[15] Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet J, et al. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the international RDC/TMD consortium network* and orofacial pain special interest group[†]. The Journal of Oral & Facial Pain and Headache. 2014; 28: 6–27.
- [16] Manfredini D, Guarda-Nardini L, Winocur E, Piccotti F, Ahlberg J, Lobbezoo F. Research diagnostic criteria for temporomandibular disorders: a systematic review of axis I epidemiologic findings. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology. 2011; 112: 453–462.
- ^[17] Ziegeler C, May A. Facial presentations of migraine, TACs, and other paroxysmal facial pain syndromes. Neurology. 2019; 93: e1138–e1147.
- ^[18] Wieckiewicz M, Grychowska N, Nahajowski M, Hnitecka S, Kempiak K, Charemska K, *et al.* Prevalence and overlaps of headaches and pain-related temporomandibular disorders among the polish urban population. The Journal of Oral & Facial Pain and Headache. 2020; 34: 31–39.
- [19] Fernandes G, Arruda MA, Bigal ME, Camparis CM, Gonçalves DAG. Painful temporomandibular disorder is associated with migraine in adolescents: a case-control study. The Journal of Pain. 2019; 20: 1155– 1163.
- [20] International classification of orofacial pain, 1st edition (ICOP). Cephalalgia. 2020; 40: 129–221.
- [21] Yakkaphan P, Smith JG, Chana P, Renton T, Lambru G. Temporomandibular disorder and headache prevalence: a systematic review and meta-analysis. Cephalalgia Reports. 2022; 5: 25158163221097352.
- [22] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008–2012.
- [23] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ. 2021; 372: n71.
- [24] Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews. 2016; 5: 210.
- [25] Kumar A, Brennan MT. Differential diagnosis of orofacial pain and temporomandibular disorder. Dental Clinics of North America. 2013; 57: 419–428.
- [26] Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, *et al.* Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLOS ONE. 2016; 11: e0147601.
- [27] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. The BMJ. 2003; 327: 557–560.
- [28] Franco AL, Gonçalves DA, Castanharo SM, Speciali JG, Bigal ME, Camparis CM. Migraine is the most prevalent primary headache in

individuals with temporomandibular disorders. Journal of Orofacial Pain. 2010; 24: 287–292.

- [29] Gonçalves DA, Camparis CM, Speciali JG, Franco AL, Castanharo SM, Bigal ME. Temporomandibular disorders are differentially associated with headache diagnoses. The Clinical Journal of Pain. 2011; 27: 611– 615.
- [30] Gonçalves MC, Florencio LL, Chaves TC, Speciali JG, Bigal ME, Bevilaqua-Grossi D. Do women with migraine have higher prevalence of temporomandibular disorders? Brazilian Journal of Physical Therapy. 2013; 17: 64–68.
- [31] van der Meer HA, Speksnijder CM, Engelbert RHH, Lobbezoo F, Nijhuisvan der Sanden MWG, Visscher CM. The Association between headaches and temporomandibular disorders is confounded by bruxism and somatic symptoms. The Clinical Journal of Pain. 2017; 33: 835–843.
- [32] Wagner BA, Moreira Filho PF, Bernardo VG. Association of bruxism and anxiety symptoms among military firefighters with frequent episodic tension type headache and temporomandibular disorders. Arquivos de Neuro-Psiquiatria. 2019; 77: 478–484.
- [33] Ashraf J, Zaproudina N, Suominen A, Sipilä K, Närhi M, Saxlin T. Association between temporomandibular disorders pain and migraine: results of the health 2000 survey. The Journal of Oral & Facial Pain and Headache. 2019; 39: 399–407.
- [34] Benoliel R, Sela G, Teich S, Sharav Y. Painful temporomandibular disorders and headaches in 359 dental and medical students. Quintessence International. 2011; 42: 73–78.
- [35] Fenton BT, Goulet JL, Bair MJ, Cowley T, Kerns RD. Relationships between temporomandibular disorders, MSD conditions, and mental health comorbidities: findings from the veterans musculoskeletal disorders cohort. Pain Medicine. 2018; 19: S61–S68.
- [36] Florencio LL, de Oliveira AS, Carvalho GF, Dach F, Bigal ME, Fernández-de-las-Peñas C, *et al.* Association between severity of temporomandibular disorders and the frequency of headache attacks in women with migraine: a cross-sectional study. Journal of Manipulative and Physiological Therapeutics. 2017; 40: 250–254.
- [37] Gonçalves DA, Bigal ME, Jales LC, Camparis CM, Speciali JG. Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache. 2010; 50: 231–241.
- [38] Plesh O, Adams SH, Gansky SA. Self-reported comorbid pains in severe headaches or migraines in a us national sample. Headache. 2012; 52: 946–956.
- [39] Song HS, Shin JS, Lee J, Lee YJ, Kim MR, Cho JH, et al. Association between temporomandibular disorders, chronic diseases, and ophthalmologic and otolaryngologic disorders in Korean adults: a crosssectional study. PLOS ONE. 2018; 13: e0191336.
- [40] Schur EA, Afari N, Furberg H, Olarte M, Goldberg J, Sullivan PF, et al. Feeling bad in more ways than one: comorbidity patterns of medically unexplained and psychiatric conditions. Journal of General Internal Medicine. 2007; 22: 818–821.
- [41] Stuginski-Barbosa J, Macedo HR, Eduardo Bigal M, Speciali JG. Signs of temporomandibular disorders in migraine patients: a prospective, controlled study. The Clinical Journal of Pain. 2010; 26: 418–421.
- [42] Steele JG, Lamey PJ, Sharkey SW, Smith GM. Occlusal abnormalities, pericranial muscle and joint tenderness and tooth wear in a group of migraine patients. Journal of Oral Rehabilitation. 1991; 18: 453–458.
- [43] Glaros A, Urban D, Locke J. Headache and temporomandibular disorders: evidence for diagnostic and behavioural overlap. Cephalalgia. 2007; 27: 542–549.
- [44] Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurology. 2009; 8: 679–690.
- [45] Bevilaqua-Grossi D, Lipton R, Napchan U, Grosberg B, Ashina S, Bigal M. Temporomandibular disorders and cutaneous allodynia are associated in individuals with migraine. Cephalalgia. 2010; 30: 425–432.
- [46] Yun P, Kim Y. The role of facial trauma as a possible etiologic factor in temporomandibular joint disorder. Journal of Oral and Maxillofacial Surgery. 2005; 63: 1576–1583.
- [47] Porto De Toledo I, Stefani FM, Porporatti AL, Mezzomo LA, Peres MA, Flores-Mir C, *et al.* Prevalence of otologic signs and symptoms in adult patients with temporomandibular disorders: a systematic review and meta-analysis. Clinical Oral Investigations. 2017; 21: 597–605.

- [48] Plesh O, Adams SH, Gansky SA. Temporomandibular joint and muscle disorder-type pain and comorbid pains in a national US sample. Journal of Orofacial Pain. 2011; 25: 190–198.
- [49] Lin CS. Brain signature of chronic orofacial pain: a systematic review and meta-analysis on neuroimaging research of trigeminal neuropathic pain and temporomandibular joint disorders. PLOS ONE. 2014; 9: e94300.
- [50] Yin Y, He S, Xu J, You W, Li Q, Long J, *et al.* The neuro-pathophysiology of temporomandibular disorders-related pain: a systematic review of structural and functional MRI studies. The Journal of Headache and Pain. 2020; 21: 78.
- [51] Weiller C, May A, Limmroth V, Jüptner M, Kaube H, Schayck RV, et al. Brain stem activation in spontaneous human migraine attacks. Nature Medicine. 1995; 1: 658–660.
- [52] Manfredini D, Piccotti F, Ferronato G, Guarda-Nardini L. Age peaks of different RDC/TMD diagnoses in a patient population. Journal of Dentistry. 2010; 38: 392–399.
- [53] Lövgren A, Häggman-Henrikson B, Visscher CM, Lobbezoo F, Marklund S, Wänman A. Temporomandibular pain and jaw dysfunction at different ages covering the lifespan—a population based study. European Journal of Pain. 2016; 20: 532–540.
- [54] Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. The Journal of Headache and Pain. 2017; 18: 37.
- [55] Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. Journal of Craniomandibular Disorders. 1992; 6: 301–355.
- [56] Nicholson RA, Houle TT, Rhudy JL, Norton PJ. Psychological risk factors in headache. Headache. 2007; 47: 413–426.
- [57] Fillingim RB, Ohrbach R, Greenspan JD, Knott C, Diatchenko L, Dubner R, *et al.* Psychological factors associated with development of TMD: the OPPERA prospective cohort study. THE Journal of Pain. 2013; 14: T75–T90.
- [58] Manfredini D, Favero L, Del Giudice A, Masiero S, Stellini E, Guarda-Nardini L. Axis II psychosocial findings predict effectiveness of TMJ hyaluronic acid injections. International Journal of Oral and Maxillofacial Surgery. 2013; 42: 364–368.
- [59] Lobbezoo F, Ahlberg J, Raphael KG, Wetselaar P, Glaros AG, Kato T, et al. International consensus on the assessment of bruxism: report of a work in progress. Journal of Oral Rehabilitation. 2018; 45: 837–844.
- [60] Mejersjö C, Ovesson D, Mossberg B. Oral parafunctions, piercing and signs and symptoms of temporomandibular disorders in high school students. Acta Odontologica Scandinavica. 2016; 74: 279–284.
- [61] Xu L, Cai B, Fan S, Dai K. Association of oral behaviors with anxiety, depression, and jaw function in patients with temporomandibular disorders in china: a cross-sectional study. Medical Science Monitor. 2021; 27: e929985.
- [62] Colonna A, Guarda-Nardini L, Ferrari M, Manfredini D. COVID-19 pandemic and the psyche, bruxism, temporomandibular disorders triangle. CRANIO. 2021; 1–6.
- [63] Manfredini D, Lobbezoo F. Role of psychosocial factors in the etiology of bruxism. Journal of Orofacial Pain. 2009; 23: 153–166.
- [64] Kothari SF, Visser M, Timmerman K, Baad-Hansen L, Koutris M, Lobbezoo F, *et al.* Painful and non-painful symptoms evoked by experimental bracing and thrusting of the mandible in healthy individuals. Journal of Oral Rehabilitation. 2021; 48: 1004–1012.
- [65] Gallo LM, Iwasaki LR, Gonzalez YM, Liu H, Marx DB, Nickel JC. Diagnostic group differences in temporomandibular joint energy densities. Orthodontics & Craniofacial Research. 2015; 18: 164–169.
- [66] Réus J, Polmann H, Souza B, Flores-Mir C, Bittencourt P, Winocur E, et al. Association between primary headache and bruxism: an updated systematic review. The Journal of Oral & Facial Pain and Headache. 2021; 35: 129–138.
- [67] Fernandes G, Franco AL, Gonçalves DA, Speciali JG, Bigal ME, Camparis CM. Temporomandibular disorders, sleep bruxism, and primary headaches are mutually associated. Journal of Orofacial Pain. 2013; 27: 14–20.
- [68] Colonna A, Cerritelli L, Lombardo L, Vicini C, Marchese-Ragona R, Guarda-Nardini L, *et al.* Temporal relationship between sleep-time masseter muscle activity and apnea-hypopnea events: a pilot study. Journal of Oral Rehabilitation. 2022; 49: 47–53.

- [69] Speciali JG, Dach F. Temporomandibular dysfunction and headache disorder. Headache. 2015; 55: 72–83.
- [70] Manrriquez SL, Robles K, Pareek K, Besharati A, Enciso R. Reduction of headache intensity and frequency with maxillary stabilization splint therapy in patients with temporomandibular disorders-headache comorbidity: a systematic review and meta-analysis. Journal of Dental Anesthesia and Pain Medicine. 2021; 21: 183–205.
- [71] Goncalves DA, Camparis CM, Speciali JG, Castanharo SM, Ujikawa LT, Lipton RB, *et al.* Treatment of comorbid migraine and temporomandibular disorders: a factorial, double-blind, randomized, placebo-controlled study. Journal of Orofacial Pain. 2013; 27: 325–335.
- [72] Tchivileva IE, Ohrbach R, Fillingim RB, Lim PF, Giosia MD, Ribeiro-Dasilva M, *et al.* Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial. Cephalalgia. 2021; 41: 839–850.
- [73] Tresoldi M, Dias R, Bracci A, Segù M, Guarda-Nardini L, Manfredini D. Magnetic resonance imaging evaluation of closed-mouth tmj disccondyle relationship in a population of patients seeking for temporomandibular disorders advice. Pain Research and Management. 2021; 2021: 5565747.
- [74] Manfredini D, Guarda-Nardini L. Agreement between research diagnostic criteria for temporomandibular disorders and magnetic resonance diagnoses of temporomandibular disc displacement in a patient population. International Journal of Oral and Maxillofacial Surgery. 2008; 37: 612– 616.
- [75] May A, Svensson P. One nerve, three divisions, two professions and nearly no crosstalk? To be published in Cephalalgia. 2017. [Preprint].

- [76] Bender SD. Temporomandibular disorders, facial pain, and headaches. Headache. 2012; 52: 22–25.
- ^[77] Sharav Y, Katsarava Z, Charles A. Facial presentations of primary headache disorders. Cephalalgia. 2017; 37: 714–719.
- [78] Lambru G, Elias L, Yakkaphan P, Renton T. Migraine presenting as isolated facial pain: a prospective clinical analysis of 58 cases. Cephalalgia. 2020; 40: 1250–1254.
- [79] Bigal ME, Lipton RB. The differential diagnosis of chronic daily headaches: an algorithm-based approach. The Journal of Headache and Pain. 2007; 8: 263–272.
- [80] Tchivileva IE, Ohrbach R, Fillingim RB, Greenspan JD, Maixner W, Slade GD. Temporal change in headache and its contribution to the risk of developing first-onset temporomandibular disorder in the orofacial pain: prospective evaluation and risk assessment (OPPERA) study. Pain. 2017; 158: 120–129.
- [81] Byun SH, Min C, Yoo DM, Yang BE, Choi HG. Increased risk of migraine in patients with temporomandibular disorder: a longitudinal follow-up study using a national health screening cohort. Diagnostics. 2020; 10: 724.

How to cite this article: Paolo Bizzarri, Daniele Manfredini, Michail Koutris, Marco Bartolini, Luca Buzzatti, Cecilia Bagnoli, *et al.* Temporomandibular disorders in migraine and tension-type headache patients: a systematic review with metaanalysis. Journal of Oral & Facial Pain and Headache. 2024; 38(2): 11-24. doi: 10.22514/jofph.2024.011.